Abstract
Serum prostate markers, in particular prostate-specific antigen (PSA), have truly revolutionised all aspects of the management of men with prostatic carcinoma (PCa), the most important application being related to its early detection and screening. Several studies have shown the clinical utility of PSA levels for staging patients with PCa, especially when associated with other parameters, such as tumour grade, digital rectal examination and transrectal ultrasound findings, to establish the likelihood of disease extension outside the gland and of positive lymph nodes. Also, serum PSA levels are useful in monitoring patients either after the initial diagnosis of PCa or following therapy.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received: 8 October 1999 / Accepted: 18 January 2000
Rights and permissions
About this article
Cite this article
Montironi, R., Mazzucchelli, R., Algaba, F. et al. Prostate-specific antigen as a marker of prostate disease. Virchows Archiv 436, 297–304 (2000). https://doi.org/10.1007/s004280050450
Issue Date:
DOI: https://doi.org/10.1007/s004280050450